IQVIA Holdings Inc. $IQV Stock Sold by Washington Trust Advisors Inc.

Key Points

• Washington Trust Advisors reduced its IQVIA position by 3.9% in the third quarter, selling 4,755 shares and retaining 116,186 shares worth approximately $31.2 million. Institutional investors collectively own 89.62% of IQVIA.
• Analysts remain broadly bullish, with IQVIA receiving a consensus “Moderate Buy” rating and an average price target of $278.75; several firms recently raised their targets to between $290 and $324.
• IQVIA reported quarterly adjusted earnings of $3.15 per share, exceeding estimates, while revenue rose 8.7% year over year to $4.37 billion. The stock recently traded at $279.47, near its 12-month high of $282.98.

Washington Trust Advisors Inc. lessened its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 3.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 116,186 shares of the medical research company's stock after selling 4,755 shares during the period. IQVIA makes up 2.2% of Washington Trust Advisors Inc.'s portfolio, making the stock its 13th biggest position. Washington Trust Advisors Inc. owned approximately 0.07% of IQVIA worth $31,237,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of IQV. Yousif Capital Management LLC grew its position in IQVIA by 1.9% in the 3rd quarter. Yousif Capital Management LLC now owns 19,608 shares of the medical research company's stock worth $5,272,000 after purchasing an additional 373 shares during the last quarter. MBL Wealth LLC acquired a new stake in shares of IQVIA in the third quarter valued at approximately $348,000. NBT Bank N.A. bought a new stake in shares of IQVIA during the third quarter valued at approximately $602,000. Root Financial Partners LLC bought a new stake in shares of IQVIA during the third quarter valued at approximately $156,000. Finally, Arvest Investments Inc. boosted its position in shares of IQVIA by 3.4% during the third quarter. Arvest Investments Inc. now owns 6,747 shares of the medical research company's stock worth $1,814,000 after buying an additional 220 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on IQV shares. Wall Street Zen raised IQVIA from a "hold" rating to a "buy" rating in a report on Saturday, September 12th. Stifel Nicolaus lifted their target price on IQVIA from $276.00 to $303.00 and gave the company a "buy" rating in a research note on Wednesday, October 14th. Weiss Ratings raised IQVIA from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, September 24th. Evercore boosted their price target on IQVIA from $275.00 to $290.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 6th. Finally, Robert W. Baird increased their price target on IQVIA from $287.00 to $324.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 29th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and an average price target of $278.75.

Insider Transactions at IQVIA

In other news, insider W. Richard Staub sold 5,500 shares of IQVIA stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the transaction, the insider directly owned 13,312 shares in the company, valued at approximately $3,097,436.16. This trade represents a 29.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Keriann Cherofsky sold 558 shares of the business's stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the sale, the insider directly owned 2,989 shares in the company, valued at $732,932.69. This represents a 15.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 15,581 shares of company stock valued at $3,796,021 over the last three months. 1.70% of the stock is owned by company insiders.

IQVIA Price Performance

Shares of IQV stock traded up $1.15 during midday trading on Friday, reaching $279.47. 981,209 shares of the company were exchanged, compared to its average volume of 1,322,001. The company's 50 day moving average price is $263.98 and its two-hundred day moving average price is $216.43. The company has a market cap of $46.00 billion, a P/E ratio of 34.67, a PEG ratio of 2.45 and a beta of 1.17. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $282.98. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion during the quarter, compared to analysts' expectations of $4.30 billion. During the same period last year, the firm posted $2.81 earnings per share. The business's revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 11.54 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.